CN116761601A - 依达拉奉口服给药用医药组合物及其给药方法 - Google Patents

依达拉奉口服给药用医药组合物及其给药方法 Download PDF

Info

Publication number
CN116761601A
CN116761601A CN202180075839.XA CN202180075839A CN116761601A CN 116761601 A CN116761601 A CN 116761601A CN 202180075839 A CN202180075839 A CN 202180075839A CN 116761601 A CN116761601 A CN 116761601A
Authority
CN
China
Prior art keywords
administration
edaravone
pharmaceutical composition
hours
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180075839.XA
Other languages
English (en)
Chinese (zh)
Inventor
清水秀俊
仲丸善喜
西村祐贵子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116761601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN116761601A publication Critical patent/CN116761601A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180075839.XA 2020-11-12 2021-11-12 依达拉奉口服给药用医药组合物及其给药方法 Pending CN116761601A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020188514 2020-11-12
JP2020-188514 2020-11-12
PCT/JP2021/041673 WO2022102737A1 (ja) 2020-11-12 2021-11-12 エダラボン経口投与用医薬組成物およびその投与方法

Publications (1)

Publication Number Publication Date
CN116761601A true CN116761601A (zh) 2023-09-15

Family

ID=81602356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180075839.XA Pending CN116761601A (zh) 2020-11-12 2021-11-12 依达拉奉口服给药用医药组合物及其给药方法

Country Status (11)

Country Link
US (2) US11911366B2 (cg-RX-API-DMAC7.html)
EP (1) EP4245303A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022102737A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230098267A (cg-RX-API-DMAC7.html)
CN (1) CN116761601A (cg-RX-API-DMAC7.html)
AR (1) AR124062A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021380319B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198014A1 (cg-RX-API-DMAC7.html)
IL (1) IL302533A (cg-RX-API-DMAC7.html)
TW (1) TW202228678A (cg-RX-API-DMAC7.html)
WO (1) WO2022102737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036261A2 (en) * 2022-08-10 2024-02-15 Kpr U.S., Llc Occlusion detection system and method for a flow control apparatus
EP4559463A1 (en) * 2023-11-23 2025-05-28 Ferrer Internacional, S.A. Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
US20190328712A1 (en) * 2017-01-17 2019-10-31 Treeway Tw001 B.V. Treatment comprising oral or gastric administration of edaravone
WO2020091036A1 (ja) * 2018-11-02 2020-05-07 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤
CN111840218A (zh) * 2016-03-16 2020-10-30 苏州澳宗生物科技有限公司 依达拉奉剂型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
JP7012792B2 (ja) 2020-08-06 2022-01-28 株式会社 ディー・エヌ・エー 動画を配信するためのシステム、方法、及びプログラム
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111840218A (zh) * 2016-03-16 2020-10-30 苏州澳宗生物科技有限公司 依达拉奉剂型
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
US20190328712A1 (en) * 2017-01-17 2019-10-31 Treeway Tw001 B.V. Treatment comprising oral or gastric administration of edaravone
CN110461325A (zh) * 2017-01-17 2019-11-15 萃微Tw001公司 包括口服或胃部施用依达拉奉的治疗
WO2020091036A1 (ja) * 2018-11-02 2020-05-07 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SHIMIZU, H,等: "Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, vol. 12, no. 01, 31 January 2023 (2023-01-31), pages 77 - 84 *
崔金凤,等: "LC-UV法测定大鼠血浆中依达拉奉及其药动学研究", 药物分析杂志 ., vol. 32, no. 09, 30 September 2012 (2012-09-30), pages 1634 - 1637 *
王婵娟;亢留玉;李玉萍;邹艳丽;梁孟波;敖英;汪晖;: "依达拉奉对实验性高脂血症小鼠的影响", 中国心血管病研究, no. 08, 10 August 2008 (2008-08-10), pages 67 - 69 *

Also Published As

Publication number Publication date
US12478611B2 (en) 2025-11-25
TW202228678A (zh) 2022-08-01
US20220142982A1 (en) 2022-05-12
JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2022-05-19
AU2021380319B2 (en) 2025-03-20
IL302533A (en) 2023-07-01
US11911366B2 (en) 2024-02-27
AU2025203773A1 (en) 2025-06-12
WO2022102737A1 (ja) 2022-05-19
KR20230098267A (ko) 2023-07-03
US20240173297A1 (en) 2024-05-30
AR124062A1 (es) 2023-02-08
EP4245303A4 (en) 2024-10-09
CA3198014A1 (en) 2022-05-19
EP4245303A1 (en) 2023-09-20
JP2025061070A (ja) 2025-04-10
AU2021380319A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
ES2388310T7 (es) Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
JP2025061070A (ja) エダラボン経口投与用医薬組成物およびその投与方法
WO2003068209A1 (en) Metformin salts of lipophilic acids
US12569469B2 (en) Pharmaceutical composition for oral administration of edaravone and method of administering same
CN103989677A (zh) 去亚甲基小檗碱在制备降血糖药物中的应用
SE459899B (sv) Anvaendning av pyridoxin - - ketoglutarat foer framstaellning av en farmaceutisk komposition foer profylax av hypermjoelksyraemi
CN103919775A (zh) 9-去甲基小檗碱在制备降血糖药物中的应用
CN109922801A (zh) 甲硝唑和巴氯芬的混悬剂和稀释剂
KR101671008B1 (ko) TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물
EP0401056B2 (en) Glutamine in the treatment of impaired host defences
JP2010111646A (ja) 潰瘍性大腸炎治療剤
JP2019034953A (ja) 体重増加用化合物の長期使用のための組成物と方法
EP2668851A1 (en) Liver function-improving agent
CN110755434A (zh) 化合物palosuran防治骨骼肌萎缩等疾病的用途
Morgan et al. Severe peripheral neuropathy complicating legionnaires' disease
Giner et al. Effect of intravenous or intragastric nutrients on food intake in rats
US10973886B2 (en) Use of a pharmaceutical composition containing at least one digestive enzyme in artificial feeding
JP2010265186A (ja) 貧血予防用組成物
CN111643501A (zh) Gensci073或其类似物的用途
KR20250099117A (ko) 도파민을 포함하는 약학적 주사용액
CN121985954A (zh) 用于减少与体重减轻相关的肌肉减少和/或抑制肌肉减少症的方法和组合物
JP2001226285A (ja) 小腸成長促進組成物
Vanderhoof et al. DEMONSTRATION OF All ADEQUATE BARRIER TO GASTROESOPHAGEAL REFLUX IN THE NEWBORN AND PRETERM INFANT
Pennington Enteral Nutrition
UA11567U (en) Method for correcting metabolic disorders in patients with metabolic syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Japan

Address after: Osaka Japan

Applicant after: Tanabe Seiyaku Co.,Ltd.

Address before: Osaka Japan

Applicant before: MITSUBISHI TANABE PHARMA Corp.

Country or region before: Japan